Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To evaluate whether simtuzumab (formerly referred to as GS-6624) can reduce portal venous pressure and incidence of clinical events in subjects with cirrhosis due to NASH.
Critère d'inclusion
- Compensated Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)